Lipid lowering in patients with coronary artery disease: low density lipoprotein cholesterol and beyond.
Now that the importance of LDL-C and its reduction are well established in the prevention of atherosclerotic vascular complications, we are moving to a new era in which physicians must pay more attention to factors beyond LDL-C lowering. More emphasis should be put on TRL and remnant lipoproteins as well as other contributors to the cardiovascular risk burden, such as thrombotic risk factors and impaired fibrinolysis. This should be carried out within the standard framework of a global approach to risk factor management in CAD patients.